Nesina Approval History 
- FDA approved: Yes (First approved January 25th, 2013)
- Brand name: Nesina
- Generic name: alogliptin
- Previous name: SYR-322
- Company: Takeda Pharmaceutical Company Limited
- Treatment for: Diabetes, Type 2
Nesina (alogliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes.
FDA Approval History for Nesina
| Date | Article |
|---|
| Jan 25, 2013 |  Takeda Receives FDA Approval for Nesina (alogliptin) for Type 2 Diabetes |
| Jul 27, 2012 | Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone |
| Apr 27, 2012 | Takeda Receives Complete Response Letter from the FDA for Type 2 Diabetes Investigational Therapies Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone |
| Apr 26, 2012 | Furiex Confirms Takeda's Receipt of Complete Response Letter from the FDA for Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone |
| Nov 18, 2011 | U.S. Food and Drug Administration (FDA) Delays Review of Takeda's Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone |
| Nov 1, 2011 | Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone |
| Jul 26, 2011 | Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone |
| Aug 28, 2009 | Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes |
| Jun 28, 2009 | Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes |
| Mar 6, 2009 | Takeda Receives New Information on Alogliptin (SYR-322) NDA |
| Dec 24, 2008 | Takeda Receives New Action Date for Alogliptin (SYR-322) NDA |
| Oct 10, 2008 | FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes |
| Feb 29, 2008 | PPD Confirms Takeda's NDA Filing of Alogliptin with U.S. Food and
Drug Administration |
| Jan 4, 2008 | Takeda Submits New Drug Application for Alogliptin (SYR-322) in the
U.S. |
See also...
Nesina (alogliptin) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
